Pham Quang Hoa

Pham Quang Hoa

Auto-generated profile, based on publicly available information

Pham Quang Hoa

Center for Personalized Precision Medicine of Tuberculosis, Inje University College of Medicine, Busan, Republic of Korea; Department of Pharmacology and PharmacoGenomics Research Center, Inje University College of Medicine, Busan, Republic of Korea

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2022 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
SSSoedarsono Soedarsono
Soedarsono Soedarsono
RJRannissa Puspita Jayanti
Rannissa Puspita Jayanti
NMNi Made Mertaniasih
Ni Made Mertaniasih
TKTutik Kusmiati
Tutik Kusmiati
APAriani Permatasari
Ariani Permatasari
Jae-Gook ShinJae-Gook Shin
Jae-Gook Shin
No population pharmacokinetics (PK) model of isoniazid (INH) has been reported for the Indonesian population with tuberculosis (TB). Therefore, we aimed to develop a population PK model to optimize pharmacotherapy of INH on the basis of therapeutic drug monitoring (TDM) implementation in Indonesian patients with TB. INH concentrations, N-acetyltransferase 2 (NAT2) genotypes, and clinical data were collected from Dr. Soetomo General Academic Hospital, Indonesia. A nonlinear mixed-effect model was used to develop and validate the population PK model. A total of 107 patients with TB (with 153 samples) were involved in this study. A one-compartment model with allometric scaling for bodyweight effect described well the PK of INH. The NAT2 acetylator phenotype significantly affected INH clearance. The mean clearance rates for the rapid, intermediate, and slow NAT2 acetylator phenotypes were 55.9, 37.8, and 17.7 L/h, respectively. Our model was well-validated through visual predictive checks and bootstrapping. We established the population PK model for INH in Indonesian patients with TB using the NAT2 acetylator phenotype as a significant covariate. Our Bayesian forecasting model should enable optimization of TB treatment for INH in Indonesian patients with TB.

16 November 2023 in International Journal of Antimicrobial Agents
Verified
Journal Article
Open access
PHPham Quang Hoa
Pham Quang Hoa
HKHyun Kuk Kim
Hyun Kuk Kim
TJTae Won Jang
Tae Won Jang
HSHyewon Seo
Hyewon Seo
JOJee Youn Oh
Jee Youn Oh
Jae-Gook ShinJae-Gook Shin
Jae-Gook Shin
Rifampicin (RIF) exhibits high pharmacokinetic (PK) variability among individuals; a low plasma concentration might result in unfavorable treatment outcomes and drug resistance. This study evaluated the contributions of non- and genetic factors to the interindividual variability of RIF exposure, then suggested initial doses for patients with different weight bands. This multicenter prospective cohort study in Korea analyzed demographic and clinical data, the solute carrier organic anion transporter family member 1B1 (SLCO1B1) genotypes, and RIF concentrations. Population PK modeling and simulations were conducted using nonlinear mixed-effect modeling. In total, 879 tuberculosis (TB) patients were divided into a training dataset (510 patients) and a test dataset (359 patients). A one-compartment model with allometric scaling for effect of body size best described the RIF PKs. The apparent clearance (CL/F) was 16.6% higher among patients in the SLCO1B1 rs4149056 wild-type group than among patients in variant group, significantly decreasing RIF exposure in the wild-type group. The developed model showed better predictive performance compared with previously reported models. We also suggested that patients with body weights of 70 kg patients receive RIF doses of 450, 600, 750, and 1050 mg/day, respectively. Total body weight and SLCO1B1 rs4149056 genotypes were the most significant covariates that affected RIF CL/F variability in Korean TB patients. We suggest initial doses of RIF based on World Health Organization weight-band classifications. The model may be implemented in treatment monitoring for TB patients.

30 April 2022 in Healthcare Informatics Research
Verified
Journal Article
Open access
PDF file
VNVan Lam Nguyen
Van Lam Nguyen
PHPham Quang Hoa
Pham Quang Hoa
NLNguyen Phuoc Long
Nguyen Phuoc Long
SASangzin Ahn
Sangzin Ahn
YCYong-Soon Cho
Yong-Soon Cho
Jae-Gook ShinJae-Gook Shin
Jae-Gook Shin

7 May 2023 in International Journal of Antimicrobial Agents
Verified
Journal Article
Open access
THTran Minh Hung
Tran Minh Hung
RJRannissa Puspita Jayanti
Rannissa Puspita Jayanti
HLHo Young Lee
Ho Young Lee
HKHyo-Jung Kim
Hyo-Jung Kim
JMJeongha Mok
Jeongha Mok
Jae-Gook ShinJae-Gook Shin
Jae-Gook Shin
The ability of ethambutol (EMB) to suppress bacterial resistance has been demonstrated in a time-dependent manner. Through the development of a population pharmacokinetics (PK) model, this study aimed to suggest the PK/pharmacodynamics (PD) target and identify the significant covariates that influence interindividual variability (IIV) in the PK of EMB. In total, 837 patients from 20 medical centres across Korea were enrolled in this study. The non-linear mixed-effect method was used to establish and validate the population PK model. A two-compartment model with transit compartment absorption was sufficient to describe the PK of EMB. Body weight and renal function were identified as significant covariates that affect IIV of the apparent clearance (CL/F) of EMB. Patients with moderate renal function showed 35% and 55% lower CL/F (CL/F 89.9 L/h) compared with those with mild and normal renal function, respectively. All the renal function groups with simulated doses ranging from 800 to 1200 mg achieved area under the curve over minimum inhibitory concentration (MIC) >119, and maintained T>MIC for >23 h for MIC of 0.5 µg/mL. Based on our simulation result, it is suggested that doses of 800, 1000, and 1200 mg should obtain the T>MIC target of 4, 6, and 8 h, respectively. This model was validated internally and externally. This study provides insight into the PK/PD indexes of EMB for three different renal function groups and T>MIC targets for different doses. The results could be used to provide optimal-dose suggestions for EMB.